Compare Novartis AG (NVS) vs Sana Biotechnology Inc (SANA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novartis AG vs Sana Biotechnology Inc — how do they compare? Novartis AG trades at $153.88 (market cap $290.25B), while Sana Biotechnology Inc trades at $3.17 (market cap $873.84M). The key difference: Novartis AG is far larger — about 332.2× Sana Biotechnology Inc's market cap, and Novartis AG pays a 3.17% dividend while Sana Biotechnology Inc pays none. Which is the better fit depends on your goals.
| NVS | SANA | |
|---|---|---|
Market Cap | $290.25B | $873.84M |
Sector | Health | Health |
52-Week High | $168.62 | $5.92 |
52-Week Low | $113.50 | $2.68 |
Enterprise Value | $330.27B | $848.03M |
Dividend Yield | 3.17% | — |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →
